All In MedTech

Device Trial Radar · NCT07868068

Detection of Blood in the GI Lumen With HemoPill Acute

Detection of Blood in the GI Lumen With HemoPill Acute - Relation Between Endoscopy and HemoPill Acute Measurement

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jul 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Stony Brook UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ovesco Endoscopy AG
First posted
Oct 9, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the HemoPill acute (trial device) can detect the presence of blood in participants suspected of having upper gastrointestinal bleeding. The main question it aims to answer is: -What is the clinical relationship between the HemoPill acute (trial device) and endoscopy (control procedure) in detecting the presence of blood/bleeding in the upper gastrointestinal tract? Participants will: * Swallow the HemoPill acute device one (1) to four (4) hours before their scheduled standard of care endoscopy procedure. * Keep the device receiver close to their body from the time of swallowing until completion of their endoscopy procedure. * Return for a follow-up visit(s) to check for the presence or absence of the HemoPill acute device and to report the occurrence of any adverse or serious adverse events.

Conditions

  • Upper GI Bleeding

Interventions

  • HemoPill acuteDevice

    Participants will ingest the HemoPill acute device one (1) to four (4) hours before their scheduled standard of care endoscopy procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and specificityTime frame: From enrollment to the end of the endoscopic examination.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stony Brook University

    Stony Brook, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.